Treatment of Parkinsonâ€™s-related Depression
Company Founded Year
Company Number of Employees
Biotechnology & Biopharmaceutical
N2B Ltd is developing an intranasal delivery formulation of the approved drug Rasagiline for the treatment of depression associated with Parkinsonâ€™s disease (PD). The company is on a quick regulatory pathway for NDA submission through the U.S. FDA 5O5(b)(2) approach.
N2Bâ€™s preclinical results indicate that intranasal delivery of Rasagiline could provide both a useful alternative to oral administration in the treatment of PD and a novel therapeutic approach for the treatment of depression in PD patients.
N2B was founded as an incubator company of Youdim Pharmaceuticals.